DrugPipeline.net has announced the addition of “Chemotherapy Induced Neutropenia (CIN) -Market Insights, Epidemiology and Market Forecast-2023” research report to their website DrugPipeline.net
Bangalore, Karnataka -- (SBWIRE) -- 03/30/2017 -- "Chemotherapy Induced Neutropenia (CIN) – Market Insights, Epidemiology and Market Forecast-2023" Report provides an overview of the disease and global market trends of the Chemotherapy Induced Neutropenia for the seven major markets i.e., United States, Europe (France, Germany, Italy, Spain, UK) and Japan, as well as rest of Europe (RoE) and rest of the world (RoW). The Report covers the therapeutics market revenue, treatment practice and Chemotherapy Induced Neutropenia (CIN) forecasted market share from 2017 to 2023 segmented by seven major markets. In addition, the report provides the historical and forecasted data of incident cases at risk of Chemotherapy Induced Neutropenia (CIN) in 10 cancer indications till 2023.
The report covers the number of patients for 10 cancer indications (i.e. Breast Cancer, Leukemia, Prostate Cancer, Lung Cancer, Cervical Cancer, Pancreatic Cancer, Colorectal Cancer, Ovarian Cancer, Hodgkin's disease and Non-Hodgkin Lymphoma), who are at risk of developing CIN as an adverse event of the chemotherapies of respective cancers.
Neupogen (Filgrastim), developed and marketed by Amgen is the first G-CSF approved for chemotherapy-induced neutropenia (CIN) in 1991. Its PEGylated formulation, Neulasta was later approved in 2002. Filgrastim i.e., Neupogen and PEGylated filgrastim (Neulasta) contribute to majority of the market size, of CIN. However, New Chemical Entities are expected to launch in the near future. According to Publisher, the Global Market size of CIN in 2016 was USD 3.67 Billion.
The report is built using data and information sourced from proprietary databases, primary and secondary research and in-house Forecast model analysis by Publisher team of industry experts.
Spanning over 132 pages "Chemotherapy Induced Neutropenia (CIN) -Market Insights, Epidemiology and Market Forecast-2023" report covers Report Introduction, Chemotherapy Induced Neutropenia (CIN) Market Overview at a Glance, Overview, Causes of Neutropenia, Appendix, Report Methodology.
For more information Visit at: http://www.drugpipeline.net/delveinsight/chemotherapy-induced-neutropenia-cin-market-insights-epidemiology-and-market-forecast
DrugPipeline.net is a market research reports distribution platform which hosts research reports from all leading global market research firms related to pharma industry. It also assist decision makers locate the right market research solution from a single place.